儿童卵巢Sertoli-Leydig细胞瘤术后戈舍瑞林保护卵巢功能1例

    A Case of Goserelin for Ovarian Function Protection After Surgery for Ovarian Sertoli-Leydig Cell Tumor In A Child

    • 摘要:
      目的  总结临床药师参与1例10岁卵巢Sertoli-Leydig细胞瘤(Sertoli-Leydig cell tumor,SLCT)患儿术后应用戈舍瑞林联合TC方案通常指紫杉醇(T)+卡铂(C)化疗保护卵巢功能的临床实践,为儿童恶性卵巢肿瘤患者的卵巢功能保护提供参考。
      方法  临床药师通过分析1例10岁中-低分化SLCT患儿术后接受紫杉醇联合卡铂化疗并联合戈舍瑞林保护卵巢功能的病例,结合文献复习,探讨促性腺激素释放激素激动剂(gonadotropin-releasing hormone agonist,GnRH-a)在儿童卵巢恶性肿瘤患者中卵巢保护的机制、有效性和临床管理策略。
      结果  戈舍瑞林作为GnRH-a,通过抑制下丘脑-垂体-卵巢(hypothalamic-pituitary-ovarian,HPO)轴使卵巢处于低促性腺激素状态,减少化疗药物对卵巢的损伤。本病例在充分知情同意前提下采用化疗联合戈舍瑞林方案,为儿童罕见卵巢恶性肿瘤的卵巢功能保护提供了临床实践经验。
      结论 戈舍瑞林的卵巢保护作用在乳腺癌患者中已获得高质量循证医学证据支持,但在卵巢恶性肿瘤及儿童青少年患者中应用证据仍有限,本病例可为该领域的临床实践提供参考。

       

      Abstract:
      OBJECTIVE To provide reference for ovarian function protection in pediatric malignant ovarian tumor patients by summarizing the clinical practice of clinical pharmacists participating in a case of goserelin combined with TC(paclitaxel plus carboplatin) chemotherapy for ovarian function protection in a 10-year-old girl with ovarian Sertoli-Leydig cell tumor(SLCT) after surgery.
      METHODS Clinical pharmacists analyzed the case of a 10-year-old girl with moderately-poorly differentiated SLCT who received paclitaxel plus carboplatin chemotherapy combined with goserelin for ovarian function protection after surgery, and explored the mechanism, efficacy and clinical management strategies of gonadotropin-releasing hormone agonist(GnRH-a) in ovarian protection in pediatric patients with ovarian malignant tumors through literature review.
      RESULTS Goserelin, a GnRH-a, reduces chemotherapy-induced ovarian damage by suppressing the hypothalamic-pituitary-ovarian(HPO) axis and maintaining the ovaries in a low gonadotropin state. In this case, the strategy of chemotherapy combined with goserelin was implemented based on full informed consent, providing clinical practice experience for ovarian function protection in pediatric rare ovarian malignancies.
      CONCLUSION The ovarian protective effect of goserelin is well supported by high-quality evidence in breast cancer patients, whereas evidence for its use in ovarian malignancies and in pediatric and adolescent patients remains limited. This case provides a clinical reference for ovarian function protection in this setting.

       

    /

    返回文章
    返回